Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group

NCT00265291 Phase 2 COMPLETED

Our goal is to study pharmacogenetics in Mexican-Americans, using depression treatments as a proof of the concept that pharmacogenetic approaches can be used to optimize treatment strategies for common and complex disorders in this population.

Details

Lead sponsor	National Institute of General Medical Sciences (NIGMS)
Phase	Phase 2
Status	COMPLETED
Enrolment	700
Start date	1999-11
Completion	2008-10

Conditions

• Major Depressive Disorder
• Major Depression
• Unipolar Depression

Interventions

• fluoxetine or desipramine

Primary outcomes

• The Hamilton Depression Rating Scale (HAM-D) on a weekly basis — 8 weeks

Countries

United States